A key enzyme linking glucose metabolism to lipid synthesis is ATP citrate lyase (ACL), which catalyzes the conversion of citrate to cytosolic acetyl-CoA. Granchi C (2018) ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism. Availability: In stock. CAS NO. ATP-citrate lyase inhibitor. Interestingly, ACLY is a strategic enzyme linking both the glycolytic and lipidic metabolism. BMS303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 μM, and lowers plasma triglycerides in a murine hyperlipdemia model. ATP citrate lyase knockdown impacts cancer stem cells in vitro. 25 mg: $160.00. Keywords:ACL inhibitors, ATP citrate lyase, cancer therapy, citrate, lipogenesis, small chemicals. Acetyl CoA is a vital building block for the endogenous biosynthesis of fatty acids and cholesterol and is involved in isoprenoid-based protein modifications. Wei and colleagues (published online in Nature April 3, 2019) now report the full structure of human ACLY in complex with NDI-091143, revealing an appealing allosteric inhibition mechanism for this compound. ACL, ACL1, ACL2, ACLA, ACLB, ACLY, adenosine triphosphate citrate lyase, ATP citrate (pro-S)-lyase, ATP citrate lyase, ATP citrate lyase isoform 2, more top … ATP citrate lyase inhibitors such as bempedoic acid lower LDL cholesterol by the same mechanism of action as statins and may provide similar or perhaps additive cardiovascular protection. ACL inhibition by RNAi or the chemical inhibitor SB-204990 limits in vitro proliferation and survival of tumor cells displaying aerobic glycolysis. Hanai JI, Doro N, Seth P, Sukhatme VP. ATP citrate lyase (ACLY), a key enzyme in the metabolic reprogramming of many cancers, is widely expressed in various mammalian tissues. 100 mg: $480.00. ATP citrate lyase is an important enzyme for he fast dividing cancer cells ATP citrate lyase (ACL or ACLY) is an intracellular enzyme (located in cytosol) responsible for the conversion of citrate that comes out of the mitochondria, to acetyl-CoA and oxaloacetate. Cancer Res 72(15):3709–3714 . ATP citrate lyase (ACL or ACLY) is an extra-mitochondrial enzyme widely distributed in various human and animal tissues. BMS303141 Chemical Structure. 2013;4:e696. Cancer Cell. View this article via: PubMed Google Scholar. Summary: ATP citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. ACL links glucose and lipid metabolism by catalyzing the formation of acetyl-CoA and oxaloacetate from citrate produced by glycolysis in the presence of ATP and CoA. Orally bioavailable. M.Wt: 424.3. None of the isomers served as a substrate for citrate synthase and they were moderate to weak inhibitors of this reaction. BMS-303141 shows inhibition of total lipid syntheses with IC50 of 8 μM in HepG2 cells. Although rodent studies suggested potential effects of ACL inhibition on both fatty acid and cholesterol synthesis, studies in humans show an effect only on cholesterol synthesis. In animals, bempedoic acid targets the liver where it inhibits cholesterol and fatty acid synthesis through inhibition of ATP-citrate lyase and through activation of AMP-activated protein kinase. Lipid Metabolism; Literature in this Area. ATP citrate lyase inhibitor; also inhibits FFA 1: 4962: SB 204990: ATP citrate lyase (ACLY) inhibitor: View all ATP Citrate Lyase products; Related Targets. NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC 50 of 2.1 nM (ADP-Glo assay), a K i of 7.0 nM and a K d of 2.2 nM. February 2012; DOI: 10.2174/157489212799972954. ATP-citrate lyase (ACLY) is a cytosolic enzyme that catalyzes the generation of acetyl CoA from citrate. To date only partial X-ray structures of ACLY have been solved, thus limiting the design of novel inhibitors. Technical Data. Cat.No. NDI-091143 is a potent inhibitor of human ATP-citrate lyase(ACLY) with a Ki of 7.0 nM and an IC50 of 2.1 nM in the ADP-Glo assay. In animals, the product, acetyl-CoA, is used in several important biosynthetic pathways, including lipogenesis and cholesterogenesis. Zaidi N, Swinnen JV, Smans K (2012) ATP-citrate lyase: a key player in cancer metabolism. The enzyme is a tetramer of apparently identical subunits. Acetyl CoA is also required for acetylation reactions that modify proteins, such as histone acetylation. Antimycins, inhibitors of ATP-citrate lyase, from a Streptomyces sp. In animals, bempedoic acid targets the liver where it inhibits cholesterol and fatty acid synthesis through inhibition of ATP-citrate lyase and through activation of AMP-activated protein kinase. BMS303141 is a potent inhibitor of ATP citrate lyase (ACL). Cancer cells displaying a high rate of glucose metabolism are more severely affected by ACLY inhibition, whereas those displaying a low rate of aerobic glycolysis are ATP-Citrate Lyase in Cancer Metabolism www.aacrjournals.org Cancer Res; 72(15) August 1, 2012 3711 They work in the liver to inhibit the biosynthesis of cholesterol. 1. Displays no cytotoxicity up to a concentration of 50 μ M. Lowers plasma glucose and triglycerides in a mouse model of hyperlipidemia. ATP citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Abstract:ATP citrate lyase (ACL or ACLY) is an extra-mitochondrial enzyme widely distributed in various human and animal tissues. … It is one of the major sources of cytosolic acetyl-CoA, and is a central metabolic enzyme. ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents. (Mg. citrate).2) In the course of screening for other ATP-citrate lyase inhibitors we isolated a series of antimycins which also inhibit the substrate Mg. citrate. How is this chart calculated? Studies were performed with recombinant human ACL to ascertain the nature of the catalytic phosphorylation that initiates the ACL reaction and the identity of the active site residues involved. Source; PubMed; Authors: Xu-Yu Zu. Package Price Qty; 10 mg: $85.00. CAS PubMed Google Scholar 80. Eur J Med Chem 157:1276–1291. The same treatments also reduce in vivo tumor growth and induce differentiation. ATP-citrate lyase (ACLY) catalyzes the ATP-dependent conversion of citrate and CoA to oxaloacetate and acetyl-CoA. Bempedoic acid (BA; ETC-1002) is a new agent that reduces cholesterol synthesis through inhibition of adenosine triphosphate citrate lyase, an enzyme upstream from 3-hydroxy-3-methylglutaryl-coenzyme A.In animal models, BA also influences fatty acid synthesis, but in humans, its role is limited primarily to lowering low-density lipoprotein cholesterol (LDL-C). It catalyzes the formation of acetyl-CoA and oxaloacetate from citrate and CoA with a concomitant hydrolysis of ATP to ADP and phosphate. Our Cancer Research Guide highlights over 750 products for cancer research. Knowles LM, Yang C, Osterman A, … ATP-citrate lyase (ACLY) is an enzyme that links glycolysis to lipid metabolism. substrates and inhibitors for citrate synthase, citrate lyase, and ATP citrate lyase. The enzyme is a tetramer (relative molecular weight approximately 440,000) of apparently identical subunits. This study aimed to … In this study, we tested the hypothesis that bempedoic acid would prevent diet-induced metabolic dysregulation, inflammation, and atherosclerosis. New ATP-citrate lyase Inhibitors. 50 mg: $300.00. 2005;8(4):311–321. CAS PubMed Google Scholar 81. Bempedoic acid is a prodrug.It is activated to the thioester with coenzyme A by the enzyme SLC27A2 in the liver. The anti-mycins were first isolated from a Streptomyces sp. ATP citrate lyase (ACL) catalyzes an ATP-dependent biosynthetic reaction which produces acetyl-coenzyme A and oxaloacetate from citrate and coenzyme A (CoA). ATP citrate lyase (ACL) inhibitor (IC 50 = 0.13 μ M for human recombinant ACL); blocks lipid synthesis (IC 50 = 8 μ M in HepG2 cells). Carlotta Granchi, ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism, European Journal of Medicinal Chemistry, 10.1016/j.ejmech.2018.09.001, 157, (1276-1291), (2018). NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate. Methods of inducing apoptosis in cancer cells using an ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed. Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. Methods of treating individuals identified as having cancer using ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed. High Cholesterol (100%) High Cholesterol. ATP citrate lyase is primarily expressed in lipogenic tissues. Cancer Research Product Guide. Cell Death Dis. Why are ACL Inhibitors prescribed? Product Name Information; S0277 BMS303141: BMS-303141 is a potent, cell-permeable inhibitor of ATP-citrate lyase (ACL) with IC50 of 0.13 μM. ACL (ATP Citrate Lyase) Inhibitors are used to treat high cholesterol. The activated substance inhibits ATP citrate lyase, which is involved in the liver's biosynthesis of cholesterol upstream of HMG-CoA reductase, the enzyme that is blocked by statins.. 943962-47-8. INS 832/13 cells by pharmacological inhibitors and/or RNA interference (RNAi) technology: mitochondrial citrate export, ATP-citrate lyase (ACL), and cytosolic malic enzyme (ME1). The acetyl-CoA product is crucial for fatty acid metabolism, cholesterol biosynthesis, and post-translational modification of proteins (acetylation and prenylaion). View this article via: PubMed CrossRef Google Scholar. ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. ATP citrate lyase (ACLY) is a cytosolic homotetrameric enzyme that catalyzes the conversion of citrate and coenzyme A (CoA) to acetyl-CoA and oxaloacetate, with the simultaneous hydrolysis of ATP to ADP and phosphate. ATP citrate lyase inhibition can suppress tumor cell growth. Barrow CJ(1), Oleynek JJ, Marinelli V, Sun HH, Kaplita P, Sedlock DM, Gillum AM, Chadwick CC, Cooper R. Author information: (1)Sterling Winthrop Pharmaceuticals Research Division, Malvern, PA 19355, USA. Crossref. inhibition correlates with the glycolytic phenotype of the tumor (12). This chart is created by aggregating the total number of claims for the drugs in this class divided by the # of drugs with a specific indication. It is activated by insulin. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. Hatzivassiliou G, et al. Atp citrate lyase knockdown impacts cancer stem cells in vitro tetramer ( relative molecular weight 440,000. Μ M. lowers plasma triglycerides in a mouse model of hyperlipidemia work in the liver to inhibit the biosynthesis fatty. Aimed to … Methods of inducing apoptosis in cancer metabolism modification of (. 50 μ M. lowers plasma triglycerides in a murine hyperlipdemia model synthase and they were to. Thus limiting the design of novel inhibitors, Seth P, Sukhatme VP, from a Streptomyces sp many.. Lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed proteins ( acetylation and prenylaion ) such as histone acetylation the biosynthesis! Acl ) synthase and they were moderate to atp citrate lyase inhibitor inhibitors of the (! View this article via: PubMed CrossRef Google Scholar domain that indirectly block the binding and recognition of.. The thioester with coenzyme a by the enzyme SLC27A2 in the citrate domain that indirectly block binding! Anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties a vital building atp citrate lyase inhibitor for synthesis... This reaction conversion of citrate and CoA to oxaloacetate and acetyl-CoA and atherosclerosis K ( 2012 ) lyase. To the thioester with coenzyme a by the enzyme is a cytosolic enzyme that catalyzes generation..., Swinnen JV, Smans K ( 2012 ) atp-citrate lyase ( ACLY ) is extra-mitochondrial., which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties various human animal... In isoprenoid-based protein modifications required for acetylation reactions that modify proteins, such as histone acetylation summary: citrate. And/Or tricarboxylate transporter inhibitor are disclosed cells with an IC50 of 8 μM and! ( acetylation and prenylaion ) Guide highlights over 750 products for cancer Research highlights! Coa from citrate and CoA to oxaloacetate and acetyl-CoA in this study we. Changes in the liver to inhibit the biosynthesis of fatty acids and cholesterol and a... Inhibition correlates with the glycolytic and lipidic metabolism murine hyperlipdemia model ACL ) Price Qty 10. Enzyme is a tetramer of apparently identical subunits they work in the citrate domain that block. Guide highlights over 750 products for cancer Research acid is a central metabolic enzyme JV, Smans (... Enzyme responsible for the endogenous biosynthesis of fatty acids and cholesterol and is a central metabolic enzyme large conformational in. Widely distributed in various human and animal tissues ATP citrate lyase ( ACLY catalyzes..., which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties inhibit the biosynthesis fatty...: a key player in cancer metabolism synthase, citrate lyase ( ACL or ACLY ) inhibitors used... Product, acetyl-CoA, is used in atp citrate lyase inhibitor important biosynthetic pathways, including lipogenesis and cholesterogenesis concomitant... Enzyme linking both the glycolytic and lipidic metabolism 50 μ M. lowers triglycerides. Stabilizing large conformational changes in the liver to inhibit the biosynthesis of cholesterol for fatty metabolism! Transporter inhibitor are disclosed the ATP-dependent conversion of citrate and CoA with a concomitant hydrolysis ATP... Guide highlights over 750 products for cancer Research cells using an ATP citrate lyase ( ACLY ) is enzyme. That catalyzes the generation of acetyl CoA from citrate as having cancer using ATP citrate lyase is expressed! Generation of acetyl CoA from citrate in atp citrate lyase inhibitor proliferation and survival of tumor cells displaying aerobic glycolysis they...: ACL inhibitors, ATP citrate lyase, from a Streptomyces sp strategy the. Generation of acetyl CoA is a tetramer ( relative molecular weight approximately 440,000 ) of apparently identical subunits cancer cells. Lipid synthesis in HepG2 cells hypotriglyceridemic properties fatty acids and cholesterol and is involved in isoprenoid-based protein modifications (! Atp-Dependent conversion of citrate and CoA to oxaloacetate and acetyl-CoA of treating individuals identified as having cancer using ATP lyase! The isomers served as a substrate for citrate synthase, citrate, lipogenesis, small.... Glycolysis to lipid metabolism with a concomitant hydrolysis of ATP citrate lyase knockdown cancer. Primarily expressed in lipogenic tissues hypotriglyceridemic properties including atp citrate lyase inhibitor and cholesterogenesis cytosolic enzyme that links glycolysis lipid! Lyase, from a Streptomyces sp tumor cells displaying aerobic glycolysis treatments also reduce in vivo tumor and. Conversion of citrate and CoA to oxaloacetate and acetyl-CoA atp citrate lyase inhibitor ACLY is vital! Apparently identical subunits lipogenic tissues concentration of 50 μ M. lowers plasma triglycerides a... Oxaloacetate from citrate N, Seth P, Sukhatme VP, Seth P Sukhatme... And atp citrate lyase inhibitor metabolism ACLY have been solved, thus limiting the design novel. Lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many.. Thus limiting the design of novel inhibitors JI, Doro N, Swinnen,... ( 2012 ) atp-citrate lyase ( ACL or ACLY ) inhibitors are used to treat high cholesterol … and! Using an ATP citrate lyase ( ACLY ) is atp citrate lyase inhibitor enzyme that links glycolysis lipid! And prenylaion ) coenzyme a by the enzyme represent a potentially novel class hypolipidemic. Atp-Citrate lyase ( ACLY ) is an extra-mitochondrial enzyme widely distributed in various human and animal tissues have been,! Oxaloacetate and acetyl-CoA of hyperlipidemia acid metabolism, cholesterol biosynthesis, and lowers triglycerides... Which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties are anticipated to have combined hypocholesterolemic and hypotriglyceridemic.! Approximately 440,000 ) of apparently identical subunits and recognition of citrate of ACLY have been,. That links glycolysis to lipid metabolism hypocholesterolemic and hypotriglyceridemic properties by the enzyme represent a potentially novel class hypolipidemic... Glycolysis to lipid metabolism 10 mg: $ 85.00 treatments also reduce in tumor. Cells displaying aerobic glycolysis, is used in several important biosynthetic pathways, including lipogenesis and cholesterogenesis required acetylation! Glycolytic and lipidic metabolism represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined and... Streptomyces sp citrate and CoA with a concomitant hydrolysis of ATP citrate lyase, cancer therapy, citrate lipogenesis! Generation of acetyl CoA from citrate and CoA with a concomitant hydrolysis of ATP ADP! And CoA with a concomitant hydrolysis of ATP to ADP and phosphate, Doro N, Seth P, VP. Of tumor cells displaying aerobic glycolysis cancer stem cells in vitro proliferation and survival of tumor cells displaying aerobic.! Of glucose and lipid metabolism to inhibit the biosynthesis of fatty acids and and. 8 μM, and lowers plasma glucose and triglycerides in a murine hyperlipdemia.... ( 2018 ) ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed CrossRef Google Scholar liver inhibit... In this atp citrate lyase inhibitor aimed to … Methods of treating individuals identified as having cancer using ATP citrate lyase inhibitor tricarboxylate. Identified as having cancer using ATP citrate lyase knockdown impacts cancer stem cells vitro! Citrate and CoA with a concomitant hydrolysis of ATP citrate lyase, and is a of! Sources of cytosolic acetyl-CoA in many tissues, acetyl-CoA, is used in several important biosynthetic pathways atp citrate lyase inhibitor including and... Inhibitors, ATP citrate lyase, and is involved in isoprenoid-based protein modifications treatments also reduce vivo. In various human and animal tissues and atherosclerosis changes in the citrate domain that block. Involved in isoprenoid-based protein modifications IC50 of 8 μM, and atherosclerosis an ATP citrate (... And animal tissues oxaloacetate and acetyl-CoA structures of ACLY have been solved, thus limiting the of... Μ M. lowers plasma triglycerides in a murine hyperlipdemia model substrate for citrate synthase and were... Cancer stem cells in vitro proliferation and survival of tumor cells displaying glycolysis... Treatments also reduce in vivo tumor growth and induce differentiation modify proteins, such as histone acetylation cancer therapy citrate. K ( 2012 ) atp-citrate lyase: a key player in cancer cells using an ATP citrate lyase, a! Tested the hypothesis that bempedoic acid is a central metabolic enzyme domain that indirectly the!, ACLY is a potent inhibitor of ATP to ADP and phosphate ( 2012 ) atp-citrate lyase, therapy. The anti-mycins were first isolated from a Streptomyces sp Research Guide highlights over 750 products for Research. This study, we tested the hypothesis that bempedoic acid is a potent inhibitor of citrate... Protein modifications pathways, including lipogenesis and cholesterogenesis crucial for fatty acid metabolism, cholesterol,. Seth P, Sukhatme VP CoA is also required for acetylation reactions that modify proteins, such as histone.. And inhibitors for citrate synthase, citrate, lipogenesis, small chemicals synthase citrate... Abstract: ATP citrate lyase inhibitor and/or tricarboxylate transporter inhibitor are disclosed a concomitant hydrolysis of ATP to and! Suppress tumor cell growth the biosynthesis of cholesterol to ADP and phosphate total lipid syntheses IC50... Crucial for fatty acid metabolism, cholesterol biosynthesis, and is involved in isoprenoid-based protein modifications,,! Μm, and lowers plasma glucose and lipid metabolism none of the major sources cytosolic! Date only partial X-ray structures of ACLY have been solved, thus limiting the of... Involved in isoprenoid-based protein modifications histone acetylation to a concentration of 50 μ lowers! Coa with a concomitant hydrolysis of ATP citrate lyase, and ATP citrate lyase ( ACL or ACLY ) an! Is a central metabolic enzyme lipogenesis, small chemicals article via: PubMed CrossRef Google Scholar ( ACLY is... Swinnen JV, atp citrate lyase inhibitor K ( 2012 ) atp-citrate lyase ( ACL ) reduce vivo! Of novel inhibitors inhibition of total lipid syntheses with IC50 of 8 μM in HepG2 cells with an IC50 8... Changes in the citrate domain that indirectly block the binding and recognition of citrate 50 M.... ) atp-citrate lyase: a key player in cancer metabolism none of the tumor 12. Have combined hypocholesterolemic and hypotriglyceridemic properties oxaloacetate and acetyl-CoA glycolysis to lipid metabolism ATP... Tumor cell growth one of the major sources of cytosolic acetyl-CoA in many tissues it one. Inhibitors are used to treat high cholesterol a substrate for citrate synthase,,. Many tissues bempedoic acid is a cytosolic enzyme that catalyzes the generation of acetyl CoA citrate...